Across TCGA pan-cancer cohorts, CC2D2B RNA is linked to patient survival in 19 of 34 cancer types, making it the most broadly survival-associated CC2D2B data layer compared with 4 for mutation status.
The strongest signal is observed in adrenocortical carcinoma (ACC), where higher CC2D2B RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated CC2D2B expression acts as an unfavorable survival marker, although some lineages such as LUAD and SKCM show a favorable association.
ACC, LUAD, and SKCM are the cancer types where CC2D2B RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.